A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
about
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutationsIncreased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in CambodiaLow-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in NigeriaIn vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptaseThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutationsTransmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.HIV-1 antiretroviral drug therapy.Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaquesComparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineClinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.HIV reverse-transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in envelope sequences.The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.
P2860
Q28235418-33BB3DB2-922D-4479-ACC1-9FC0367D996FQ28535850-EC84BD27-8EBB-4759-9C6C-E7C06084A560Q33602033-00DD1974-3DEF-4321-A5B5-5870164A19CCQ33625367-18728943-2818-47A8-8D8D-2F29F710A8FFQ33857855-B429BB80-A8CF-41CF-80AD-067CAD60107FQ33889635-CA0521CB-500D-4C93-BEF8-638E70DCF2F4Q33959260-8F3CEA5B-1BA4-4FC8-ADC4-77B58B571B1BQ34647936-309B68E7-4163-4B2A-B3CF-EEC035C16E2EQ35122204-C830E0D1-693B-418D-A56E-6148B98E3296Q35215399-CAA71350-34DE-4B3C-9211-7E66BEB20AD8Q35784897-A2100DC7-5EAB-49A7-BC4A-5542702A95B3Q35842525-F863CE7B-2FE0-425D-BC7F-055554166E47Q35853012-D98E4DD7-F765-4547-8BC4-8A75F430267EQ35927290-FD275EA2-DFB7-48C7-94C7-D54377528448Q36250342-B967C513-356B-4FC7-8025-B2A8C462AAD3Q36684283-22DEFFCF-BA9C-4640-861C-8633AF75C189Q36852626-757B3DDB-0FCA-49C4-94F2-3343831EF163Q37859395-3EB8675D-7011-465A-BD3D-7CD28E48BF11Q39142877-0DBC45CD-9465-4E94-AF86-E1883A92EEC5Q41066820-AF01C4A0-B60F-4898-984F-3341BE5F50CAQ41766427-86D62351-510D-43D0-9C63-47350397BE4FQ42212831-0452B4E6-3DA5-456F-93E3-924F186DB54EQ46718140-F8794269-C523-4167-A12D-8B041A6296CCQ55340159-17CDFDBB-D9A4-4940-BE87-0499ABCEDB4D
P2860
A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@ast
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@en
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@nl
type
label
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@ast
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@en
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@nl
prefLabel
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@ast
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@en
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@nl
P2093
P2860
P1433
P1476
A novel genetic pathway of hum ...... mediated by the K65R mutation.
@en
P2093
Diane Bennett
Hamish MacInnes
Hillard Weinstock
J Gerardo García-Lerma
Jonathan E Kaplan
Patrick Reid
Soumya Nidtha
P2860
P304
P356
10.1128/JVI.77.10.5685-5693.2003
P407
P577
2003-05-01T00:00:00Z